Marta Capelán

555 total citations
20 papers, 321 citations indexed

About

Marta Capelán is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Marta Capelán has authored 20 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Marta Capelán's work include Cancer Treatment and Pharmacology (4 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Breast Cancer Treatment Studies (3 papers). Marta Capelán is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Breast Cancer Treatment Studies (3 papers). Marta Capelán collaborates with scholars based in United Kingdom, Spain and Belgium. Marta Capelán's co-authors include Evandro de Azambuja, Kamal S. Saini, Christos Sotiriou, Sherene Loi, Martine Piccart, Ivana Babič Božović, Lina Pugliano, Adam Sharp, Stefania Redana and Hazel Lote and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Marta Capelán

20 papers receiving 317 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marta Capelán United Kingdom 8 202 93 81 66 35 20 321
Sherry A. Goodner United States 8 200 1.0× 102 1.1× 47 0.6× 58 0.9× 28 0.8× 19 350
Maria Litwiniuk Poland 10 245 1.2× 117 1.3× 43 0.5× 74 1.1× 98 2.8× 52 442
Arthur Géraud France 9 150 0.7× 53 0.6× 27 0.3× 114 1.7× 41 1.2× 25 277
Valérie Cristina Switzerland 7 175 0.9× 70 0.8× 52 0.6× 101 1.5× 35 1.0× 15 364
Christina Yeon United States 8 258 1.3× 76 0.8× 60 0.7× 97 1.5× 70 2.0× 26 367
Kyung‐Hun Lee South Korea 11 205 1.0× 143 1.5× 41 0.5× 73 1.1× 58 1.7× 20 360
Johanna Wassermann France 12 197 1.0× 77 0.8× 90 1.1× 83 1.3× 98 2.8× 41 514
Patrick Cobb United States 14 301 1.5× 96 1.0× 30 0.4× 105 1.6× 44 1.3× 43 476
Rebecca Herbertson United Kingdom 8 153 0.8× 48 0.5× 109 1.3× 78 1.2× 22 0.6× 18 295
Anna Mucha-Małecka Poland 12 169 0.8× 145 1.6× 38 0.5× 119 1.8× 91 2.6× 46 462

Countries citing papers authored by Marta Capelán

Since Specialization
Citations

This map shows the geographic impact of Marta Capelán's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marta Capelán with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marta Capelán more than expected).

Fields of papers citing papers by Marta Capelán

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marta Capelán. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marta Capelán. The network helps show where Marta Capelán may publish in the future.

Co-authorship network of co-authors of Marta Capelán

This figure shows the co-authorship network connecting the top 25 collaborators of Marta Capelán. A scholar is included among the top collaborators of Marta Capelán based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marta Capelán. Marta Capelán is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Brasó‐Maristany, Fara, Meritxell Bellet, Mafalda Oliveira, et al.. (2021). 16P Understanding the biologic determinants of ribociclib efficacy in breast cancer. Annals of Oncology. 32. S27–S27. 1 indexed citations
3.
Heras, Begoña de las, Kamal S. Saini, Frances Boyle, et al.. (2020). Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months. SHILAP Revista de lepidopterología. 8(2). 171–182. 21 indexed citations
4.
Oliveira, Mafalda, Judit Matito, Raquel Pérez-López, et al.. (2019). Determinants of concordance in clinically relevant genes (CRG) from synchronously acquired tumor biopsies (tBx) and ctDNA in metastatic breast cancer (MBC).. Journal of Clinical Oncology. 37(15_suppl). 1075–1075. 1 indexed citations
5.
Papadatos-Pastos, Dionysis, Desam Roda, Maria J. de Miguel, et al.. (2017). Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit. European Journal of Cancer. 75. 56–62. 4 indexed citations
6.
Capelán, Marta, Desamparados Roda, Elena Geuna, et al.. (2017). Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?. Lung Cancer. 111. 6–11. 2 indexed citations
7.
Capelán, Marta, et al.. (2017). The prevalence of unmet needs in 625 women living beyond a diagnosis of early breast cancer. British Journal of Cancer. 117(8). 1113–1120. 37 indexed citations
8.
Sanmamed, Miguel F., Emilio Esteban, Ruth Zárate, et al.. (2017). Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours. Journal of Translational Medicine. 15(1). 62–62. 6 indexed citations
9.
Redana, Stefania, Adam Sharp, Hazel Lote, et al.. (2016). Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population. The Breast. 30. 13–18. 11 indexed citations
10.
Lote, Hazel, et al.. (2016). Febrile Neutropenia Rates According to Body Mass Index and Dose Capping in Women Receiving Chemotherapy for Early Breast Cancer. Clinical Oncology. 28(9). 597–603. 24 indexed citations
11.
Rafii, Saeed, Desamparados Roda, Elena Geuna, et al.. (2015). Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials. Clinical Cancer Research. 21(8). 1869–1876. 28 indexed citations
12.
Geuna, Elena, Desamparados Roda, Saeed Rafii, et al.. (2015). Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials. British Journal of Cancer. 113(11). 1541–1547. 27 indexed citations
13.
Zardavas, Dimitrios, Felipe Ades, Lina Pugliano, et al.. (2014). Controversial issues in early-stage breast cancer: a global collaborative survey, supported by the European Society for Medical Oncology (ESMO). Annals of Oncology. 25(8). 1558–1562. 4 indexed citations
14.
Molife, L. Rhoda, Marta Capelán, Nicola Cresti, et al.. (2014). Phase I/IIa trial of the novel microtubule inhibitor BAL101553 in advanced solid tumors: Phase I completed.. Journal of Clinical Oncology. 32(15_suppl). 2562–2562. 1 indexed citations
15.
Capelán, Marta, Anthony W. Tolcher, Andrea Zivi, et al.. (2013). Abstract C173: A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: Preliminary results.. Molecular Cancer Therapeutics. 12(11_Supplement). C173–C173. 3 indexed citations
16.
Gonzalez, Michael V., Matthew Chau Hsien Ng, Sarah Benafif, et al.. (2013). A first-in-human (FIH) dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous BAL101553, a novel microtubule inhibitor, in adult patients with advanced solid tumors.. Journal of Clinical Oncology. 31(15_suppl). 2566–2566. 5 indexed citations
17.
Capelán, Marta, Lina Pugliano, Evandro de Azambuja, et al.. (2012). Pertuzumab: new hope for patients with HER2-positive breast cancer. Annals of Oncology. 24(2). 273–282. 124 indexed citations
18.
Zardavas, Dimitrios, Lina Pugliano, Felipe Ades, et al.. (2012). Targeted treatments of HER2-positive metastatic breast cancer: trastuzumab and beyond. 1(3). 217–233. 2 indexed citations
19.
Fonseca, Paula Jiménez, Emilio Esteban, M. Luque, et al.. (2008). Impact of erythropoietin on the reduction of blood transfusions and on survival of lung cancer patients receiving first-line chemotherapy. Clinical & Translational Oncology. 10(7). 426–432. 3 indexed citations
20.
Esteban, Emilio, N. Villanueva, Yolanda Fernández, et al.. (2007). Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study. Investigational New Drugs. 26(1). 67–74. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sherry A. Goodner Breakdown of academic impact, for papers by Maria Litwiniuk Breakdown of academic impact, for papers by Arthur Géraud Breakdown of academic impact, for papers by Valérie Cristina Breakdown of academic impact, for papers by Christina Yeon Breakdown of academic impact, for papers by Kyung‐Hun Lee Breakdown of academic impact, for papers by Johanna Wassermann Breakdown of academic impact, for papers by Patrick Cobb Breakdown of academic impact, for papers by Rebecca Herbertson Breakdown of academic impact, for papers by Anna Mucha-Małecka
Rankless by CCL
2026